Your browser doesn't support javascript.
loading
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors.
Adra, Nabil; Vaughn, David J; Einhorn, Lawrence H; Hanna, Nasser H; Funt, Samuel A; Rosales, Matt; Arozullah, Ahsan; Feldman, Darren R.
  • Adra N; Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA. nadra@iu.edu.
  • Vaughn DJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Einhorn LH; Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA.
  • Hanna NH; Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA.
  • Funt SA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rosales M; Weill Cornell Medical College, New York, NY, USA.
  • Arozullah A; Astellas Pharma US, Inc, Northbrook, IL, USA.
  • Feldman DR; Astellas Pharma US, Inc, Northbrook, IL, USA.
Invest New Drugs ; 40(5): 1087-1094, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35759134
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Testiculares / Neoplasias de Células Germinales y Embrionarias / Anticuerpos Monoclonales / Recurrencia Local de Neoplasia / Antineoplásicos Límite: Adult / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Testiculares / Neoplasias de Células Germinales y Embrionarias / Anticuerpos Monoclonales / Recurrencia Local de Neoplasia / Antineoplásicos Límite: Adult / Humans / Male / Middle aged Idioma: En Año: 2022 Tipo del documento: Article